Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009

January 3, 2011

Osamu Yokosuka1,*, Masayuki Kurosaki2, Fumio Imazeki1, Yasuji Arase3, Yasuhito

Tanaka4, Kazuaki ma5, Eiji Tanaka6, Hiromitsu Kumada3, Namiki Izumi2,

Masashi Mizokami7, Masatoshi Kudo8Article first published online: 11 NOV 2010

DOI: 10.1111/j.1872-034X.2010.00739.x

Issue

Hepatology Research

Volume 41, Issue 1, pages 1–21, January 2011

Abstract

Recently, much progress has been made in the field of hepatitis B, such as

natural history of the disease in relation to the amount of hepatitis B virus

(HBV) DNA, genotypes of HBV influencing the natural course and treatment

effects, mutations of HBV influencing the severity of the disease and

development of hepatocellular carcinoma, and antiviral treatment such as

nucleos(t)ide analogues and pegylated interferon. To make the consensus for the

diagnosis, management and treatment of hepatitis B, a meeting was held during

45th annual meeting of Japan Society of Hepatology (JSH) in June 2009. In the

meeting, recommendations and informative statements were discussed on the

following subjects: (i) natural history of HBV infection; (ii) clinical

implication of HBV genotypes; (iii) HBV mutations and their potential impact on

pathogenesis of HBV infection; (iv) indications for antiviral treatment of

chronic hepatitis B; (v) nucleos(t)ide analogues for chronic hepatitis B; and

(vi) interferon therapy for chronic hepatitis B. The presenters reviewed the

data on these subjects and proposed the consensus statements and

recommendations. These statements were discussed among the organizers and

presenters, and were approved by the participants of the meeting. In the current

report, the relevant data were reviewed and the 12 consensus statements and nine

recommendations on chronic hepatitis B were described.

Recommended Posts